Pt (IV) Complexes as Prodrugs for Cisplatin

The antitumor effects of platinum(IV) complexes, considered prodrugs for cisplatin, are believed to be due to biological reduction of Pt(IV) to Pt(II), with the reduction products binding to DNA and other cellular targets. In this work we used pBR322 DNA to capture the products of reduction of oxopl...

Full description

Bibliographic Details
Main Authors: Shi, Yi, Liu, Shu-An, Kerwood, Deborah J., Goodisman, Jerry, Dabrowiak, James C.
Format: Text
Language:unknown
Published: SURFACE at Syracuse University 2012
Subjects:
DNA
Online Access:https://surface.syr.edu/che/41
https://surface.syr.edu/cgi/viewcontent.cgi?article=1003&context=che
id ftsyracuseuniv:oai:surface.syr.edu:che-1003
record_format openpolar
spelling ftsyracuseuniv:oai:surface.syr.edu:che-1003 2023-05-15T15:52:57+02:00 Pt (IV) Complexes as Prodrugs for Cisplatin Shi, Yi Liu, Shu-An Kerwood, Deborah J. Goodisman, Jerry Dabrowiak, James C. 2012-02-01T08:00:00Z application/pdf https://surface.syr.edu/che/41 https://surface.syr.edu/cgi/viewcontent.cgi?article=1003&context=che unknown SURFACE at Syracuse University https://surface.syr.edu/che/41 https://surface.syr.edu/cgi/viewcontent.cgi?article=1003&context=che http://creativecommons.org/licenses/by/3.0/ CC-BY Chemistry - Faculty Scholarship carbonic acid circular DNA cisplatin oxoplatin plasmid DNA platinum complex prodrugarticle DNA binding drug effect drug structure drug synthesis nonhuman reaction analysis reduction structure analysis Ascorbic Acid Carbonates Coordination Complexes DNA Circular Electrophoresis Agar Gel Electrophoretic Mobility Shift Assay Glutathione Molecular Structure Oxidation-Reduction Plasmids Platinum Prodrugs Reducing Agents Chemistry text 2012 ftsyracuseuniv 2022-01-09T19:30:40Z The antitumor effects of platinum(IV) complexes, considered prodrugs for cisplatin, are believed to be due to biological reduction of Pt(IV) to Pt(II), with the reduction products binding to DNA and other cellular targets. In this work we used pBR322 DNA to capture the products of reduction of oxoplatin, c,t,c-[PtCl 2(OH) 2(NH 3) 2], 3, and a carboxylate-modified analog, c,t,c-[PtCl 2(OH)(O 2CCH 2CH 2CO 2H)(NH 3) 2], 4, by ascorbic acid (AsA) or glutathione (GSH). Since carbonate plays a significant role in the speciation of platinum complexes in solution, we also investigated the effects of carbonate on the reduction/DNA-binding process. In pH 7.4 buffer in the absence of carbonate, both 3 and 4 are reduced by AsA to cisplatin (confirmed using 195Pt NMR), which binds to and unwinds closed circular DNA in a manner consistent with the formation of the well-known 1, 2 intrastrand DNA crosslink. However, when GSH is used as the reducing agent for 3 and 4, 195Pt NMR shows that cisplatin is not produced in the reaction medium. Although the Pt(II) products bind to closed circular DNA, their effect on the mobility of Form I DNA is different from that produced by cisplatin. When physiological carbonate is present in the reduction medium, 13C NMR shows that Pt(II) carbonato complexes form which block or impede platinum binding to DNA. The results of the study vis-à-vis the ability of the Pt(IV) complexes to act as prodrugs for cisplatin are discussed. Text Carbonic acid Syracuse University Research Facility And Collaborative Environment (SUrface)
institution Open Polar
collection Syracuse University Research Facility And Collaborative Environment (SUrface)
op_collection_id ftsyracuseuniv
language unknown
topic carbonic acid
circular DNA
cisplatin
oxoplatin
plasmid DNA
platinum complex
prodrugarticle
DNA binding
drug effect
drug structure
drug synthesis
nonhuman
reaction analysis
reduction
structure analysis
Ascorbic Acid
Carbonates
Coordination Complexes
DNA
Circular
Electrophoresis
Agar Gel
Electrophoretic Mobility Shift Assay
Glutathione
Molecular Structure
Oxidation-Reduction
Plasmids
Platinum
Prodrugs
Reducing Agents
Chemistry
spellingShingle carbonic acid
circular DNA
cisplatin
oxoplatin
plasmid DNA
platinum complex
prodrugarticle
DNA binding
drug effect
drug structure
drug synthesis
nonhuman
reaction analysis
reduction
structure analysis
Ascorbic Acid
Carbonates
Coordination Complexes
DNA
Circular
Electrophoresis
Agar Gel
Electrophoretic Mobility Shift Assay
Glutathione
Molecular Structure
Oxidation-Reduction
Plasmids
Platinum
Prodrugs
Reducing Agents
Chemistry
Shi, Yi
Liu, Shu-An
Kerwood, Deborah J.
Goodisman, Jerry
Dabrowiak, James C.
Pt (IV) Complexes as Prodrugs for Cisplatin
topic_facet carbonic acid
circular DNA
cisplatin
oxoplatin
plasmid DNA
platinum complex
prodrugarticle
DNA binding
drug effect
drug structure
drug synthesis
nonhuman
reaction analysis
reduction
structure analysis
Ascorbic Acid
Carbonates
Coordination Complexes
DNA
Circular
Electrophoresis
Agar Gel
Electrophoretic Mobility Shift Assay
Glutathione
Molecular Structure
Oxidation-Reduction
Plasmids
Platinum
Prodrugs
Reducing Agents
Chemistry
description The antitumor effects of platinum(IV) complexes, considered prodrugs for cisplatin, are believed to be due to biological reduction of Pt(IV) to Pt(II), with the reduction products binding to DNA and other cellular targets. In this work we used pBR322 DNA to capture the products of reduction of oxoplatin, c,t,c-[PtCl 2(OH) 2(NH 3) 2], 3, and a carboxylate-modified analog, c,t,c-[PtCl 2(OH)(O 2CCH 2CH 2CO 2H)(NH 3) 2], 4, by ascorbic acid (AsA) or glutathione (GSH). Since carbonate plays a significant role in the speciation of platinum complexes in solution, we also investigated the effects of carbonate on the reduction/DNA-binding process. In pH 7.4 buffer in the absence of carbonate, both 3 and 4 are reduced by AsA to cisplatin (confirmed using 195Pt NMR), which binds to and unwinds closed circular DNA in a manner consistent with the formation of the well-known 1, 2 intrastrand DNA crosslink. However, when GSH is used as the reducing agent for 3 and 4, 195Pt NMR shows that cisplatin is not produced in the reaction medium. Although the Pt(II) products bind to closed circular DNA, their effect on the mobility of Form I DNA is different from that produced by cisplatin. When physiological carbonate is present in the reduction medium, 13C NMR shows that Pt(II) carbonato complexes form which block or impede platinum binding to DNA. The results of the study vis-à-vis the ability of the Pt(IV) complexes to act as prodrugs for cisplatin are discussed.
format Text
author Shi, Yi
Liu, Shu-An
Kerwood, Deborah J.
Goodisman, Jerry
Dabrowiak, James C.
author_facet Shi, Yi
Liu, Shu-An
Kerwood, Deborah J.
Goodisman, Jerry
Dabrowiak, James C.
author_sort Shi, Yi
title Pt (IV) Complexes as Prodrugs for Cisplatin
title_short Pt (IV) Complexes as Prodrugs for Cisplatin
title_full Pt (IV) Complexes as Prodrugs for Cisplatin
title_fullStr Pt (IV) Complexes as Prodrugs for Cisplatin
title_full_unstemmed Pt (IV) Complexes as Prodrugs for Cisplatin
title_sort pt (iv) complexes as prodrugs for cisplatin
publisher SURFACE at Syracuse University
publishDate 2012
url https://surface.syr.edu/che/41
https://surface.syr.edu/cgi/viewcontent.cgi?article=1003&context=che
genre Carbonic acid
genre_facet Carbonic acid
op_source Chemistry - Faculty Scholarship
op_relation https://surface.syr.edu/che/41
https://surface.syr.edu/cgi/viewcontent.cgi?article=1003&context=che
op_rights http://creativecommons.org/licenses/by/3.0/
op_rightsnorm CC-BY
_version_ 1766388039408418816